GMP-conformant on-site manufacturing of a CD133(+) stem cell product for cardiovascular regeneration

BACKGROUND: CD133(+) stem cells represent a promising subpopulation for innovative cell-based therapies in cardiovascular regeneration. Several clinical trials have shown remarkable beneficial effects following their intramyocardial transplantation. Yet, the purification of CD133(+) stem cells is ty...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Stem Cell Res Ther
Prif Awduron: Skorska, Anna, Müller, Paula, Gaebel, Ralf, Große, Jana, Lemcke, Heiko, Lux, Cornelia A., Bastian, Manuela, Hausburg, Frauke, Zarniko, Nicole, Bubritzki, Sandra, Ruch, Ulrike, Tiedemann, Gudrun, David, Robert, Steinhoff, Gustav
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5303262/
https://ncbi.nlm.nih.gov/pubmed/28187777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13287-016-0467-0
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg